Country: United States
Language: English
Source: NLM (National Library of Medicine)
cisplatin (UNII: Q20Q21Q62J) (cisplatin - UNII:Q20Q21Q62J)
Corden Pharma Latina S.p.A.
cisplatin
cisplatin 1 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
PLATINOL (cisplatin for injection, USP) is indicated as therapy to be employed as follows: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy. PLATINOL is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. PLATINOL is contraindicated in patients with preexisting renal impairment. PLATI
PLATINOL® (cisplatin for injection, USP) NDC 61126-003-01—Each amber vial contains 50 mg of cisplatin
New Drug Application
PLATINOL- CISPLATIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION CORDEN PHARMA LATINA S.P.A. ---------- PLATINOL (CISPLATIN FOR INJECTION, USP) RX ONLY WARNING PLATINOL (cisplatin for injection, USP) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Cumulative renal toxicity associated with PLATINOL is severe. Other major dose-related toxicities are myelosuppression, nausea, and vomiting. Ototoxicity, which may be more pronounced in children, and is manifested by tinnitus, and/or loss of high frequency hearing and occasionally deafness, is significant. _Anaphylactic-like_ reactions to PLATINOL have been reported. Facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of PLATINOL administration. Epinephrine, corticosteroids, and antihistamines have been effectively employed to alleviate symptoms (see WARNINGS and ADVERSE REACTIONS). EXERCISE CAUTION TO PREVENT INADVERTENT PLATINOL OVERDOSE. Doses greater than 100 mg/m /cycle once every 3 to 4 weeks are rarely used. Care must be taken to avoid inadvertent PLATINOL overdose due to confusion with PARAPLATIN (carboplatin) or prescribing practices that fail to differentiate daily doses from total dose per cycle. DESCRIPTION PLATINOL (cisplatin for injection, USP) is a white to light yellow lyophilized powder. Each vial of PLATINOL contains 50 mg cisplatin, 450 mg Sodium Chloride, USP, and 500 mg Mannitol, USP. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl H N , and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207° C. C Read the complete document